Cabaletta Bio Inc (CABA)

$2.31 -0.03 (-1.28%)
Market Cap 235.85M
Revenue (ttm) 0.00
Net Income (ttm) -115.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,532,932
Avg Vol 4,587,590
Day's Range N/A - N/A
Shares Out 96.27M
Stochastic %K 7%
Beta 3.10
Analysts Strong Sell
Price Target $13.22

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythe...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 759 3100
Address:
2929 Arch Street, Suite 600, Philadelphia, United States
jerzypawlik
jerzypawlik Nov. 14 at 9:09 PM
$CABA Volume dropped today. I guess weak hands are almost gone. Not many sellers left, so it's going to spike fast. Especially with 1.5 days to cover, this will go ballistic again. Just wait evetyone till MM's pull the plug. They will be the ones who will cook shorts.
0 · Reply
jerzypawlik
jerzypawlik Nov. 14 at 8:36 PM
$CABA Seriously guys you have to calm down. This is oversold, and shorts don't have much time to cover. Going into weekend in short position, is the most risky, and dangerous maneuver. So don't worry bulls, shorts are those who should worry not you.
0 · Reply
Bronco6970
Bronco6970 Nov. 14 at 8:17 PM
$CABA would love to see a nice push into the close here. Come on Caba, let’s go!!
0 · Reply
Achandler787
Achandler787 Nov. 14 at 7:57 PM
$CABA go long - then you don’t have to worry about being short 😂
0 · Reply
Himtan1
Himtan1 Nov. 14 at 7:53 PM
$CABA latest dilution is on 6/11. They may do the same thing again Q2 2026. The company is far away from making money.
0 · Reply
Bronco6970
Bronco6970 Nov. 14 at 7:13 PM
$CABA I’m good right where I am, thanks. 🚀🔥
1 · Reply
Himtan1
Himtan1 Nov. 14 at 6:56 PM
$CABA KYTX got 150million loan to support their company while Steven Nichtberger chooses to dilute shares every time price go up.
0 · Reply
Himtan1
Himtan1 Nov. 14 at 6:51 PM
$CABA I'm fucked if this can't go green
0 · Reply
omholdings
omholdings Nov. 14 at 6:16 PM
$CABA shorted 10k @2.96
0 · Reply
Himtan1
Himtan1 Nov. 14 at 5:22 PM
$CABA funds are buying KYTX. They have better financial situation and fast registration speed.
0 · Reply
Latest News on CABA
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 7:30 AM EST - 4 days ago

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

Nov 4, 2025, 8:00 AM EST - 10 days ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

Oct 27, 2025, 7:00 AM EDT - 18 days ago

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

Oct 14, 2025, 8:00 AM EDT - 4 weeks ago

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

Oct 9, 2025, 12:00 PM EDT - 5 weeks ago

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon

Oct 7, 2025, 6:20 AM EDT - 5 weeks ago

Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 27, 2025, 8:00 AM EDT - 2 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:30 AM EDT - 3 months ago

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 3 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT NGNE NTLA QURE RCKT

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 9:54 AM EDT - 5 months ago

Cabaletta Bio Announces Pricing of Public Offering of Securities

Cabaletta Bio: Sector Headwinds And Funding Issues

Jun 11, 2025, 9:49 AM EDT - 5 months ago

Cabaletta Bio: Sector Headwinds And Funding Issues

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:15 AM EDT - 5 months ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

Jun 11, 2025, 6:00 AM EDT - 5 months ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 6 months ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

May 15, 2025, 7:00 AM EDT - 6 months ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 31, 2025, 7:00 AM EDT - 8 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Mar 19, 2025, 7:00 AM EDT - 8 months ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 9 months ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 10:21 AM EST - 9 months ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 9 months ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Feb 11, 2025, 8:00 AM EST - 9 months ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Jan 29, 2025, 8:00 AM EST - 10 months ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Cabaletta Bio: Finding Optimism In Dire Straits

Jan 6, 2025, 2:28 PM EST - 11 months ago

Cabaletta Bio: Finding Optimism In Dire Straits

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Oct 22, 2024, 11:41 AM EDT - 1 year ago

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 28, 2024, 1:42 PM EDT - 1 year ago

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

Jun 14, 2024, 2:00 AM EDT - 1 year ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 15, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 13, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 27, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Feb 1, 2024, 4:30 PM EST - 1 year ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 31, 2024, 2:53 AM EST - 1 year ago

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Dec 11, 2023, 5:58 AM EST - 2 years ago

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Buy Cabaletta Bio's Promising SLE Treatment

Dec 10, 2023, 2:44 AM EST - 2 years ago

Buy Cabaletta Bio's Promising SLE Treatment

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 4:30 PM EST - 2 years ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 28, 2023, 3:55 PM EST - 2 years ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Nov 6, 2023, 8:15 AM EST - 2 years ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Sep 19, 2023, 4:56 AM EDT - 2 years ago

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

Jul 24, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

Cabaletta Bio to Present at the Jefferies Healthcare Conference

May 31, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Present at the Jefferies Healthcare Conference

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

May 22, 2023, 4:30 PM EDT - 2 years ago

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

jerzypawlik
jerzypawlik Nov. 14 at 9:09 PM
$CABA Volume dropped today. I guess weak hands are almost gone. Not many sellers left, so it's going to spike fast. Especially with 1.5 days to cover, this will go ballistic again. Just wait evetyone till MM's pull the plug. They will be the ones who will cook shorts.
0 · Reply
jerzypawlik
jerzypawlik Nov. 14 at 8:36 PM
$CABA Seriously guys you have to calm down. This is oversold, and shorts don't have much time to cover. Going into weekend in short position, is the most risky, and dangerous maneuver. So don't worry bulls, shorts are those who should worry not you.
0 · Reply
Bronco6970
Bronco6970 Nov. 14 at 8:17 PM
$CABA would love to see a nice push into the close here. Come on Caba, let’s go!!
0 · Reply
Achandler787
Achandler787 Nov. 14 at 7:57 PM
$CABA go long - then you don’t have to worry about being short 😂
0 · Reply
Himtan1
Himtan1 Nov. 14 at 7:53 PM
$CABA latest dilution is on 6/11. They may do the same thing again Q2 2026. The company is far away from making money.
0 · Reply
Bronco6970
Bronco6970 Nov. 14 at 7:13 PM
$CABA I’m good right where I am, thanks. 🚀🔥
1 · Reply
Himtan1
Himtan1 Nov. 14 at 6:56 PM
$CABA KYTX got 150million loan to support their company while Steven Nichtberger chooses to dilute shares every time price go up.
0 · Reply
Himtan1
Himtan1 Nov. 14 at 6:51 PM
$CABA I'm fucked if this can't go green
0 · Reply
omholdings
omholdings Nov. 14 at 6:16 PM
$CABA shorted 10k @2.96
0 · Reply
Himtan1
Himtan1 Nov. 14 at 5:22 PM
$CABA funds are buying KYTX. They have better financial situation and fast registration speed.
0 · Reply
Bronco6970
Bronco6970 Nov. 14 at 5:05 PM
$CABA nice 🚀👊🏻
0 · Reply
KNCourt24
KNCourt24 Nov. 14 at 4:36 PM
$CABA Got a good feeling about next week I want 3’s then launch from there
0 · Reply
Bronco6970
Bronco6970 Nov. 14 at 4:33 PM
$CABA who was that who bought 15,500 shares 😉
0 · Reply
Bronco6970
Bronco6970 Nov. 14 at 4:09 PM
$CABA nice rebound
0 · Reply
Sw1ngb0t
Sw1ngb0t Nov. 14 at 3:58 PM
$CABA we've got a whole whack of low IQ strangers on here today. stop attacking me.
0 · Reply
WastedTrader
WastedTrader Nov. 14 at 3:09 PM
$CABA "EASY" 👇😂
0 · Reply
Chartist0_0
Chartist0_0 Nov. 14 at 3:06 PM
$CABA this board violates my rule of investing using ST: Too many bulls. Also, people who use the word "easy" to describe investing.
1 · Reply
Achandler787
Achandler787 Nov. 14 at 3:03 PM
$CABA go green Baby!
0 · Reply
Ahouli09
Ahouli09 Nov. 14 at 3:01 PM
$CABA adding more
0 · Reply
Stockholm111
Stockholm111 Nov. 14 at 2:56 PM
$CABA Blood bath based on macro movement. Sit tight
0 · Reply
KNCourt24
KNCourt24 Nov. 14 at 2:51 PM
$CABA that might’ve been final dip to ignite next run
1 · Reply
jerzypawlik
jerzypawlik Nov. 14 at 1:48 PM
$CABA Shorts must cover today. We'll find out today how many scare cats are left. I don't think there are many. Looks like going to be very interesting day.
1 · Reply